文献速递肾小球疾病

口服直接Xa因子抑制剂在肾病综合征患者中的安全性与有效性:全国回顾性研究

Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective Study.
PubMed 文献 · Kidney Int Rep · 2025-02-03

该多中心回顾性研究纳入2014至2022年接受治疗剂量抗凝的成人肾病综合征患者144例,比较DOAC与维生素K拮抗剂或肝素的安全性和有效性。结果显示DOAC组与标准治疗组在血栓栓塞和出血事件发生率上无显著差异,提示DOAC可用于肾病综合征的原发和继发预防。

要点

  • DOAC组与标准治疗组血栓栓塞发生率分别为4.2%和0%,无显著差异。
  • DOAC组与标准治疗组出血事件发生率分别为6.9%和13.9%,无显著差异。
  • 女性、年龄>75岁和抗凝暴露>90天为出血危险因素。

核心结论

  • 本研究表明DOAC在肾病综合征患者的原发和继发预防中比传统抗凝策略更安全有效。

研究设计与样本

  • 多中心回顾性研究,纳入2014至2022年接受治疗剂量抗凝的成人肾病综合征患者144例。
  • 排除终末期肾病患者,比较DOAC组(n=72)与标准治疗组(n=72)的出血和血栓栓塞事件。

主要发现

  • 总体人群中位年龄54岁,女性占34.7%,中位白蛋白1.5 g/dl,中位尿蛋白肌酐比8.8 g/g。
  • 膜性肾病为主要病因,占45.8%。
  • DOAC组原发预防占79.2%,标准治疗组占83.3%(P=0.67)。
  • DOAC组与标准治疗组血栓栓塞发生率分别为4.2%和0%(P=0.25),出血事件发生率分别为6.9%和13.9%(P=0.28)。
  • 单因素分析显示女性、年龄>75岁和抗凝暴露>90天为出血危险因素。

临床怎么用

  • 对于肾病综合征患者的抗凝治疗,可考虑使用DOAC作为传统抗凝策略的替代选择。
  • 对女性、年龄>75岁或抗凝暴露>90天的患者应加强出血监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The optimal management of thromboembolism (TE) in patients with nephrotic syndrome (NS) remains challenging. Until now, anticoagulation therapy for NS consisted of vitamin K antagonists (VKAs) or heparin. Data on direct oral anticoagulant (DOAC) use in NS are limited, and their safety and convenience have been well-demonstrated in other indications. METHODS: We conducted a multicenter retrospective study of adult patients with NS treated with therapeutic-dose anticoagulation between 2014 and 2022. We compared the incidences of bleeding and TE events between patients receiving DOAC and those receiving VKAs or heparin (standard-of-care [SOC]). Patients with end-stage kidney disease were excluded. RESULTS: The overall population consisted of 144 patients (median [interquartile range] age of 54 [38-67] years, 34.7% women) with a median albumin level at 1.5 (1.2-1.8) g/dl and a median urinary protein-to-creatinine ratio of 8.8 (5.5-12.3)g/g. Membranous nephropathy was the main NS etiology (45.8%). No significant differences were observed between the DOAC (n = 72) and the SOC (n = 72) groups. The anticoagulant strategy was primary prophylaxis in 79.2% of patients taking DOAC and 83.3% of patients with SOC (P = 0.67). DOAC use was not associated with an increased rate of TE (4.2% vs. 0%, P = 0.25) or bleeding events (6.9% vs. 13.9%, P = 0.28) compared with the SOC group. Univariate analysis identified female sex, age > 75 years, and anticoagulant exposure > 90 days as risk factors for bleeding. CONCLUSION: This study suggests that DOAC are safer and more effective than conventional anticoagulant strategies for both primary and secondary prophylaxis in patients with NS.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Arches C, Jalal-Eddine A, Titeca-Beauport D, et al. Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective Study. Kidney Int Rep. 2025. PMID: 40303208. doi:10.1016/j.ekir.2025.01.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。